Vaxart to Host Webcast with Important Viewpoint Leaders to Discuss the Health and fitness Influence and Sickness Stress for Norovirus

Organization to offer a detailed overview of its norovirus clinical program

Webcast to be held on March 28, 2023 at 1:00 p.m. ET

SOUTH SAN FRANCISCO, Calif., March 17, 2023 (Globe NEWSWIRE) — Vaxart, Inc. (NASDAQ: VXRT) currently declared it will host a essential feeling leader online video webcast on the overall health and financial affect and disorder stress for norovirus on Tuesday, March 28, 2023 at 1:00 p.m. ET.

The webcast will feature presentations by notable norovirus ailment professionals Jan Vinjé, Ph.D., Head, Nationwide Calicivirus Laboratory, Facilities for Sickness Handle & Avoidance, and Sarah Bartsch, Task Director, General public Health and fitness Informatics, Computational, and Operations Investigate, Analysis Foundation of the Town College of New York.

In addition, Vaxart administration will present a comprehensive overview of the Company’s investigational norovirus oral tablet vaccine program, including its two recent Section 2 clinical trials:

• An ongoing Phase 2 GI.1 norovirus obstacle review measuring the efficacy and security of our norovirus vaccine candidate. The review is also designed to recognize a correlate of security involving immune responses to the vaccine and a reduction in hazard of norovirus an infection and / or extreme gastroenteritis. The Enterprise expects to report topline data from this review in Q3 2023.

• A Period 2 dose-ranging study of Vaxart’s bivalent norovirus oral vaccine applicant is developed to determine a vaccine dose for a potential Stage 3 scientific demo. The Enterprise expects to report topline info from this analyze in mid-2023.

To sign-up for the webcast, be sure to click on right here. A replay of the webcast will be obtainable on the Company’s site at www.vaxart.com following the summary of the occasion.

About the KOLs

Jan Vinjé, Ph.D.
Dr. Vinjé is head of the Countrywide Calicivirus Laboratory and Director of CaliciNet at the Centers for Illness Management and Avoidance (CDC) in Atlanta, GA. Dr. Vinjé acquired his Ph.D. degree at the University of Utrecht, the Netherlands, in 1999. Right after receiving a postdoctoral fellowship and an appointment as research assistant professor at the College of North Carolina in Chapel Hill, he joined CDC in 2006. In excess of the earlier 10 yrs, he has served on quite a few application advisory committees from quite a few European investigate tasks (FP6, FP7). He is serving as technological professional on the norovirus subcommittee of the Nationwide Advisory Committee on Microbiological Criteria for Foodstuff and is a member of the Global Committee on Taxonomy of Viruses examine groups on Caliciviridae (chair as of 2014) and Astroviridae. He is at present a member of the editorial board of the Journal of Clinical Microbiology and associate editor of the journal Foodstuff and Environmental Virology, and he serves as an advertisement hoc reviewer for many substantial-effect journals. Dr. Vinjé has revealed more than 100 peer-reviewed publications and a number of e-book chapters. His study pursuits include things like all facets of viral gastrointestinal ailment, like detection, characterization, and prevention and control of norovirus bacterial infections.

Story carries on

Sarah M. Bartsch, MPH
Ms. Bartsch is a Task Director and Senior Analyst with General public Well being Informatics, Computational, and Operations Study (PHICOR), the Synthetic Intelligence, Modeling, and Informatics for Nutrition Guidance and Methods (AIMINGS) Centre, and the Centre for State-of-the-art Know-how and Communication in Well being (Capture), headquartered at the City College of New York (CUNY) Graduate Faculty of Community Wellness and Well being Coverage. She has been a part of the group because August of 2009 and has in excess of a ten years of practical experience making use of techniques methods and establishing mathematical and computational styles to aid a extensive vary of conclusion makers in community wellbeing. Bartsch has authored around 95 scientific publications, like far more than 30 as first creator.

About Vaxart 
Vaxart is a medical-stage biotechnology organization developing a array of oral recombinant vaccines primarily based on its proprietary supply system. Vaxart vaccines are developed to be administered employing drugs that can be stored and shipped devoid of refrigeration and eradicate the hazard of needle-stick harm. Vaxart believes that its proprietary capsule vaccine shipping and delivery system is ideal to supply recombinant vaccines, positioning the business to acquire oral variations of now promoted vaccines and to layout recombinant vaccines for new indications. Vaxart’s improvement packages at present consist of pill vaccines made to secure in opposition to norovirus, coronavirus, seasonal influenza, and respiratory syncytial virus (RSV), as nicely as a therapeutic vaccine for human papillomavirus (HPV), Vaxart’s initially immune-oncology sign. Vaxart has filed wide domestic and intercontinental patent purposes masking its proprietary technologies and creations for oral vaccination working with adenovirus and TLR3 agonists.

Take note Relating to Ahead-Hunting Statements
This press launch consists of ahead-searching statements that require substantial dangers and uncertainties. All statements, other than statements of historic points, provided in this press release about Vaxart’s technique, prospects, ideas and targets, success from preclinical and clinical trials, commercialization agreements and licenses, and beliefs and anticipations of administration are ahead-hunting statements. These forward-looking statements might be accompanied by these kinds of terms as “ought to,” “imagine,” “could,” “possible,” “will,” “anticipated,” “foresee,” “system,” and other terms and phrases of equivalent which means. Examples of these kinds of statements include things like, but are not restricted to, statements relating to Vaxart’s skill to establish and commercialize its solution candidates, including its vaccine booster solutions Vaxart’s anticipations regarding medical outcomes and trial info and Vaxart’s anticipations with respect to the effectiveness of its products candidates. Vaxart may possibly not truly realize the strategies, have out the intentions, or satisfy the anticipations or projections disclosed in the forward-seeking statements, and you really should not put undue reliance on these ahead-seeking statements. Actual success or activities could differ materially from the ideas, intentions, anticipations, and projections disclosed in the ahead-hunting statements. Numerous essential elements could cause actual results or gatherings to differ materially from the forward-searching statements that Vaxart helps make.

Be sure to also refer to the threats described in the “Chance Components” sections of Vaxart’s Quarterly and Annual Studies submitted with the SEC. Vaxart does not assume any obligation to update any forward-wanting statements, apart from as demanded by legislation.

Contacts